TSHA

Taysha Gene Therapies, Inc. [TSHA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TSHA Stock Summary

Top 10 Correlated ETFs

TSHA

Top 10 Correlated Stocks

TSHA

In the News

TSHA Financial details

Company Rating
-
Market Cap
549.83M
Income
-114M
Revenue
15.45M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
52
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.1
Forward P/E
-
PEG
0.17
P/S
25.02
P/B
-4.91
P/C
-
P/FCF
-6.87
Quick Ratio
0.91
Current Ratio
0.95
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.37
EPS next Y
-
EPS next Q
-
EPS this Y
-75.13%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-24.06%
EPS Q/Q
-127.96%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-112%
ROE
877%
ROC
-7.27%
Gross Margin
100%
Oper. Margin
-776%
Profit Margin
-1532%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.5-3.89
52W High
-
52W Low
-
RSI
33
Rel Volume
1.6
Avg Volume
2.77M
Volume
4.44M
Perf Week
-29.1%
Perf Month
-23.48%
Perf Quarter
-37.25%
Perf Half Y
-39.37%
-
-
-
-
Beta
0.262
-
-
Volatility
0.28%, 0.15%
Prev Close
-9.71%
Price
1.255
Change
-27.46%

Something similar

Top by Market Cap
FXAIX
AAPL
AMZ.DE
ABEA.DE
AVGO
Top Correlated ETFs
ERNS.L
EUSE.MI
MNA
Top Correlated Stocks
AKO-B
FORT.L
1051.HK
3339.HK
603938.SS
Similar Market Cap
DGRS
EOH.JO
PSEP
0976.HK
AMNB

Company Profile

Healthcare Biotechnology
  • Volume Average 2.77M
  • Market Capitalization 549.83M
  • Employee 52
  • CEO Mr. Sean P. Nolan
  • Headquarters Dallas,TX,US
  • IPO Date 2020-09-24
  • Website https://www.tayshagtx.com

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.